Advert - Norgine – AUTH/3365/7/20

Promotion of Feraccru

For an email comparing Feraccru capsules (ferric maltol) with intravenous iron, which did not have sufficient information for the reader to understand the basis and significance of the data and encouraging the use of Feraccru in all inflammatory bowel disease (IBD) patients when not all of those patients would be suitable for such therapy, Norgine was ruled in breach of the following clauses of the Code:


Clause 2 - Bringing discredit upon, and reducing confidence in, the pharmaceutical industry

Clause 7.2 - Making misleading claims

Clause 7.3 - Making misleading comparisons

Clause 7.4 - Making unsubstantiated claims

Clause 9.1 - Failing to maintain high standards